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Abstract
 
Accumulation of inflammatory microglia in Alzheimer’s senile plaques is a hallmark of the innate
 
response to 
 
 
 
-amyloid fibrils and can initiate and propagate neurodegeneration characteristic of
Alzheimer’s disease (AD). The molecular mechanism whereby fibrillar 
 
 
 
-amyloid activates the
inflammatory response has not been elucidated. CD36, a class B scavenger receptor, is expressed
on microglia in normal and AD brains and binds to 
 
 
 
-amyloid fibrils in vitro. We report here
that microglia and macrophages, isolated from CD36 null mice, had marked reductions in
fibrillar 
 
 
 
-amyloid–induced secretion of cytokines, chemokines, and reactive oxygen species.
Intraperitoneal and stereotaxic intracerebral injection of fibrillar 
 
 
 
-amyloid in CD36 null mice
induced significantly less macrophage and microglial recruitment into the peritoneum and
brain, respectively, than in wild-type mice. Our data reveal that CD36, a major pattern recog-
nition receptor, mediates microglial and macrophage response to 
 
 
 
-amyloid, and imply that
CD36 plays a key role in the proinflammatory events associated with AD.
Key words: microglia • scavenger receptor • Alzheimer’s disease • chemokine • reactive 
oxygen species
 
Introduction
 
The senile plaque is a key pathological feature of Alzhei-
mer’s disease (AD)
 
* 
 
and is composed of insoluble 
 
 
 
-amy-
loid fibril deposits (fA
 
 
 
), activated microglia, astrocytes,
and degenerating neurons. Data from humans with AD and
animal models of AD indicate that accumulation of in-
flammatory microglia at sites of fA
 
  
 
deposition contributes
significantly to neuronal degeneration (1–8). fA
 
  
 
itself is
believed to initiate the accumulation and activation of
microglia (5–7). Innate immune recognition of fA
 
  
 
is
therefore a key event that initiates the inflammatory cas-
cade at sites of fA
 
  
 
deposition that contributes to the
pathogenesis of AD. The molecular mechanism responsible
for fA
 
 
 
’s proinflammatory effects on microglia, however, is
not known.
Microglia are macrophage lineage immune cells of the
brain that express pattern recognition receptors, which are
thought to mediate their innate interactions with foreign or
modified host proteins. These receptors include the class A
scavenger receptor (SR-A; 9, 10), expressed in the central
nervous system exclusively on microglial cells (7, 11, 12),
and the class B scavenger receptor type 2, or CD36, which
is expressed on microglia and endothelial cells in the central
nervous system (13). SR-A promotes microglial endocyto-
sis of fA
 
  
 
but is not required for fA
 
 
 
-induced microglial
activation (10, 14). CD36 also binds fA
 
  
 
and recent data
from our lab suggests that it may play a role in fA
 
  
 
activa-
tion of microglial cells (13).
In this study, we use macrophages and microglia from
CD36-deficient mice to demonstrate that CD36 is required
for fA
 
 
 
-induced activation of these cells to produce reac-
tive oxygen species (ROS), TNF
 
 
 
, IL-1
 
 
 
, and several che-
mokines that induce microglial chemotaxis. We also show
that the absence of CD36 significantly decreased the re-
cruitment of microglia and macrophages to sites of fA
 
 
 
deposition in vivo. These data identify CD36 as a mediator
of the innate microglial response to fA
 
  
 
and suggest that
this pattern recognition receptor plays an important role in
initiating the inflammatory response in AD.
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Abbreviations used in this paper:
 
 AD, Alzheimer’s disease; CIV, collagen
 
IV; DAPI, 4
 
 
 
,6-diamidine-2
 
 
 
-phenylindole dihydrochloride; fA
 
 
 
,
 
 
 
-amyloid fibril deposits; MCP-1, monocyte chemoattractant protein 1;
MIP, macrophage inflammatory protein; NBT, nitro blue tetrazolium;
Q-PCR, quantitative real-time PCR; ROS, reactive oxygen species;
SR-A, class A scavenger receptor.T
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CD36 and Alzheimer’s Disease
 
Materials and Methods
 
Mice.
 
CD36
 
 
 
/
 
  
 
mice were generated by targeted gene dis-
ruption in murine embryonic stem cells by homologous recom-
bination (15). CD36
 
 
 
/
 
  
 
and CD36
 
 
 
/
 
  
 
littermate controls from
the mating of heterozygous CD36
 
 
 
/
 
  
 
mice in a mixed C57BL/6J
and 129/SvEv background were used for the in vitro experi-
ments. CD36
 
 
 
/
 
  
 
mice backcrossed into C57BL/6J for five gener-
ations and CD36
 
 
 
/
 
  
 
C57BL/6J mice littermates or C57BL/6J
purchased from The Jackson Laboratory were used for the in
vivo experiments. 5–6-mo-old mice were used for intraperito-
neal and intracerebral injection experiments.
 
Isolation of Primary Macrophage and Microglial Culture.
 
Thioglycollate-elicited peritoneal macrophages were harvested
from 8–12-wk-old mice as previously described (16). Primary
neonatal microglia were prepared from mixed brain cultures as
previously described (9, 13). Adult mouse microglia were pre-
pared from 5–6-mo-old CD36
 
 
 
/
 
  
 
and CD36
 
 
 
/
 
  
 
mice as previ-
ously described (17). In brief, mouse brains were cut into small
pieces (1–2 mm), vigorously triturated to obtain single cell sus-
pensions, and then passed through a percoll gradient to separate
cells from debris. Microglia were then separated from other
brain cells by differential adhesion to tissue culture–treated plas-
tic. Cells were confirmed to be 
 
 
 
95% microglia or macrophages
by staining with F4/80 and anti-CR3 antibodies and uptake of
DiI AcLDL.
 
Preparation of Fibrillar 
 
 
 
-Amyloid.
 
 
 
-Amyloid 1–42 peptide
and control peptide with identical amino acid composition but
reverse sequence (revA
 
 
 
) were obtained from American Peptide
Company or Biosource International. A
 
  
 
1
 
 
 
42 fibrils (fA
 
 
 
)
were generated and confirmed to be fibrils by several methods in-
cluding thioflavin S staining, transmission electron microscopy,
and SDS-PAGE as previously described (13).
 
Measurement of ROS Production and Adhesion Assay.
 
ROS
production was measured by nitro blue tetrazolium (NBT) re-
duction assay (13). In brief, 10
 
5 
 
peritoneal macrophages were
plated on 6-mm
 
2 
 
multispot glass slides and stimulated with HBSS
containing 1 mg/ml BSA alone, HBSS/BSA plus 10 
 
 
 
g fA
 
 
 
(1.67 
 
 
 
g/mm
 
2
 
), or 1 mg/ml zymosan for 10 min at 37
 
 
 
C. 50 
 
 
 
l
of 1 mg/ml NBT was added to each spot and cells were incu-
bated at 37
 
 
 
C for 1 h. ROS production correlates with formation
of a dark blue colored insoluble formazan deposit, which was
quantified by microscope video capture and Scion image analysis
software. Adhesion assay was performed on multispot slides
coated with collagen IV (CIV) and fA
 
  
 
as previously described in
detail (9, 18).
 
Monocyte Chemoattractant Protein 1 (MCP-1) ELISA and Chemo-
taxis Assay.
 
Cells were incubated on 6-mm
 
2 
 
multispot slides
(10
 
5 
 
cells/spot) overnight in RPMI containing 10% FCS at 37
 
 
 
C.
Cells were transferred to RPMI containing 1% FCS for 2 h and
then stimulated with 10 
 
 
 
g fA
 
 
 
, revA
 
 
 
, or 100 ng/ml of bacte-
rial LPS (Sigma-Aldrich) for 24 h. MCP-1 in supernatants was
measured by ELISA (R&D Systems). Chemotaxis assays were
performed using the Neuroprobe chemotaxis instrument (Neu-
roprobe). In brief, 31 
 
 
 
l cell supernatant or medium containing
MCP-1 (PeproTech) were placed in the lower compartment of
the chemotaxis chamber, and 50 
 
 
 
l of 10
 
6 
 
cells/ml (in RPMI
containing 1% FCS) were placed in the upper compartment.
Cells were allowed to migrate for 3 h at 37
 
 
 
C and the number of
cells migrating into the lower chamber was counted using an in-
verted light microscope. To test the effect of neutralizing anti–
MCP-1 antibodies on chemotaxis, cell supernatant or medium
containing 250 ng/ml MCP-1 were incubated with 10 
 
 
 
g/ml
goat IgG anti–mouse MCP-1 or control goat IgG (R&D Sys-
 
tems) for 30 min before initiating chemotaxis. Each data point is
the result of at least triplicate measurements and each experiment
was repeated between three and eight times.
 
Quantitative Real-Time PCR (Q-PCR).
 
2 
 
 
 
g total RNA
from each sample was reverse transcribed using multiscribe re-
verse transcriptase (Applied Biosystems). Oligonucleotide primers
were designed using Primer Express software 1.0 (Applied Bio-
systems). A series of standards was prepared by performing 10-
fold serial dilutions of full-length cDNAs in the range of 20 mil-
lion copies to 2 copies per PCR reaction. Subsequent analysis
was performed on the data output from the MX4000™ software
(Stratagene) using Microsoft Excel XP. Relative quantification of
mRNA expression was calculated by the comparative cycle
method described by the manufacturer (Stratagene).
 
Immunofluorescence Staining of Cultured Microglia and Macro-
phages.
 
Microglia and macrophages adherent to multispot
slides were fixed in ice cold methanol and stained with 2 
 
 
 
g/ml
mAb to mouse CD36 (Cascade Biologics, Inc.), followed by
1 
 
 
 
g/ml FITC-labeled secondary antibody (Sigma-Aldrich).
Stained cells were visualized by fluorescence microscopy and
digitally photographed.
 
Intraperitoneal Injection of fA
 
 
 
.
 
CD36
 
 
 
/
 
  
 
or CD36
 
 
 
/
 
  
 
mice
were injected with 1 ml PBS containing 1 mg BSA (carrier) and
100 
 
 
 
g fA
 
 
 
 or 1 mg zymosan. 24 h later, peritoneal cells were
collected by lavage with 10 ml ice cold PBS and counted. 1 ml of
the peritoneal lavage was then plated on a glass slide using
Cytospin3 (Shandon), stained with Hema 3 staining kit (Fisher
Scientific), and 500 cells from each mouse were counted.
 
Stereotaxic Brain Microinjection.
 
5–6-mo-old adult mice were
anesthetized with intraperitoneal injection of 0.1 ml saline con-
taining 2.5 mg ketamine and 0.5 mg xylazine. After mice were
immobilized in a Kopf stereotaxic apparatus, a linear skin incision
was made over the bregma, and a 1-mm burr hole was drilled in
the skull 1 mm anterior to and 2 mm lateral to the bregma on
both sides. 2 
 
 
 
l fA
 
  
 
containing 1 mg/ml solution was inoculated
on the right side using a 5-
 
 
 
l Hamilton syringe. 2 
 
 
 
l nonfibrillar
revA
 
  
 
was inoculated at the same depth and stereotaxic coordi-
nates on the left side of the brain, providing a control inoculation
in the same animal. 48 h later, the mice were anesthetized and
perfused by an intracardiac infusion of ice cold PBS containing
4% neutral paraformaldehyde (PFA-PBS) in the left ventricle.
The brains were removed, placed in 4% PFA-PBS overnight at
4
 
 
 
C, and then transferred to 30% sucrose in PBS and stored at
4
 
 
 
C until sectioning.
 
Immunohistochemistry.
 
20-
 
 
 
m frozen sections from CD36
 
 
 
/
 
 
 
and CD36
 
 
 
/
 
  
 
mice were stained for 1 h at 25
 
 
 
C with 1 nM 4
 
 
 
,6-
diamidine-2
 
 
 
-phenylindole dihydrochloride (DAPI; Molecular
Probes) and 10 
 
 
 
g/ml FITC-labeled F4/80 monoclonal anti-
body (Serotec). The sections were washed four times in PBS, and
50  l Vectashield (Vector Laboratories) was added per slide be-
fore adding the coverslips. For quantitation of the number of re-
cruited microglia to sites of microinjection, five serial sections
from each site of injection were visualized by fluorescence mi-
croscopy (magnifications,  4 and  40) and digitally photo-
graphed to record the FITC and DAPI staining. DAPI and FITC
staining were then overlaid for each section using Adobe Photo-
shop (Adobe Systems). The fluorescence intensity of FITC-
labeled microglia at each microinjection site was then quantified
using Scion’s image analysis software and used as a measure of
microglial number.
Statistical Analysis. Statistical analysis was performed using
one-way ANOVA provided in the “Microcal Origin 5” graphicsT
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and statistics software. P-values were  0.005 where considered
significant.
Results
Microglia Stimulated with fA  Secrete Mononuclear Phagocyte
Chemoattractants. To test whether fA -stimulated micro-
glia secrete mononuclear phagocyte chemoattractants, pri-
mary mouse microglia were allowed to adhere to sterile
multispot glass slides in the presence of increasing concen-
trations of fA . After 24 h, the supernatants were assayed
for chemotactic activity using the human monocyte cell line
THP-1 in a transwell chemotaxis assay. The chemotactic
activity secreted into the supernatant of microglial cell cul-
tures reached a plateau at 2.5  g/spot with a chemotactic
index of 6 (Fig. 1 A). Control nonfibrillar A  42-1 (revA )
did not induce microglia to secrete chemotactic activity for
THP-1 cells (Fig. 1 A). Medium containing fA  alone in
the lower compartment (i.e., in the absence of any previous
interaction with microglia) was not chemotactic for THP-1
cells (unpublished data). These data demonstrate that fA 
activates microglia to secrete monocyte chemoattractants.
fA -stimulated Microglia Secrete MCP-1. Having estab-
lished that fA -stimulated microglia secrete monocyte cell
chemoattractants, we proceeded to identify these chemoat-
tractants. Because MCP-1/CCL2 is a potent monocyte
chemoattractant found in senile plaques (19) and is produced
by fA -stimulated monocytes and a microglial cell line (20),
we speculated that it is also produced by fA -stimulated mi-
croglia. We measured MCP-1 levels in supernatants of fA -
stimulated primary mouse microglia using an ELISA and
found that fA -stimulated microglia secreted MCP-1 into
the medium in a dose-dependent fashion (Fig. 1 B).
We proceeded to determine what percentage of the
monocyte chemotactic activity secreted by fA -stimulated
primary microglia was due to MCP-1. Neutralizing anti-
body to MCP-1 blocked  40% of the THP-1 cell chemo-
tactic activity found in supernatants of microglia stimulated
with 10  g/spot fA  (Fig. 1 C). Control antibodies had no
effect on THP-1 migration to the identical supernatant. In
control experiments, the same neutralizing anti–MCP-1
antibody totally blocked migration of THP-1 cells in re-
sponse to 250 ng/ml MCP-1, confirming the effectiveness
of these antibodies (Fig. 1 D).
Figure 1. fA  stimulates primary mouse
microglia to produce monocyte chemotactic
activity and up-regulate chemokine mRNAs.
(A) Primary mouse microglia were cultured
on multispot slides and stimulated with the
indicated concentrations of fA  and revA .
Chemotaxis of THP-1 monocytic cells was
assayed using the Neuroprobe transwell as-
say. Chemotactic index is the number of
THP-1 cells that migrated in response to
supernatant from stimulated microglia/
number of cells that migrated in response to
supernatant from unstimulated microglia.
No significant chemotactic activity for
THP-1 cells was induced in response to the
revA  (n   8). (B) Dose response curve for
MCP-1 production measured by ELISA in
the supernatant of mouse microglia stimu-
lated with increasing concentrations of fA 
(n   3). (C) 10  g/ml anti–MCP-1 neu-
tralizing antibody partially inhibited mono-
cyte chemotactic activity produced in the
supernatant of primary mouse microglia
stimulated with 10  g/spot fA  (n   3).
Isotype-matched antibodies had no effect.
(D) 10  g/ml anti–MCP-1 neutralizing an-
tibody totally inhibited MCP-1–induced
monocyte chemotactic activity (n   3). (E)
Microglia were stimulated with 10  g/spot
fA  for 24 h and RNA was harvested for
Q-PCR measurement of the indicated che-
mokines (n   2). Each data point is the av-
erage     SEM of triplicate measurements
from the indicated number of experiments
(n). *, P   0.005.T
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1660 CD36 and Alzheimer’s Disease
fA  Stimulation Up-regulates Several Microglial Chemokine
mRNAs. Because MCP-1 accounted for only 40% of the
THP-1 cell chemotactic activity found in supernatants of
fA - stimulated microglia, we tested whether additional
chemokines are also up-regulated in these cells. Using
Q-PCR, we found that in addition to MCP-1, fA  stimu-
lation up-regulates several microglial chemokine mRNA
including macrophage inflammatory protein (MIP)-1 /
CCL3, MIP-1 /CCL4, and MIP-2/CXCL2, which have
also been described as microglial chemoattractants (Fig.
1 E). As expected, microglia incubated with equal amounts
of control revA   did not up-regulate their chemokine
mRNA levels significantly (Fig. 1 E). Not all chemokines
were induced by fA  stimulation of microglia as can be
seen by the lack of stromal cell–derived factor-1 (SDF-1)/
CXCL12, interferon-inducible T cell    chemoattractant
(I-TAC)/CXCL11, and fractalkine/CX3CL1 induction.
These data indicate that several chemokines, in addition to
MCP-1, are likely to play roles in the recruitment of mi-
croglia to senile plaques in AD.
CD36 Is Required for fA -induced Monocyte Chemoattrac-
tant Production by Microglia. To determine whether CD36
is required for production of THP-1 chemotactic activity
by mouse microglia, we used primary mouse microglia
isolated from CD36 null mice (CD36 / ) and CD36 / 
wild-type littermate controls. Supernatants collected from
CD36 /   microglia stimulated with 10  g/spot fA  pro-
duced no chemotactic activity for THP-1 cells, whereas
similarly treated CD36 /  microglia produced significant
THP-1 chemotactic activity (Fig. 2 A). CD36 /  and
CD36 /  microglia did not respond to the control revA 
peptide but produced equal amounts of chemotactic activ-
ity when stimulated with bacterial LPS, confirming that the
machinery necessary to produce chemoattractants is intact
in CD36 /  microglia. These data demonstrate an essential
role for CD36 in fA  activation of microglia to produce
monocyte chemoattractants.
CD36 Is Required for fA -induced MCP-1 Protein Secretion
and mRNA Induction. To test whether CD36 is involved
in fA -induced MCP-1 secretion, peritoneal macrophages
isolated from CD36 /  mice were stimulated with fA  and
the supernatant was analyzed for MCP-1 protein by
ELISA. MCP-1 protein was undetectable in the culture su-
pernatants of CD36 /  macrophages stimulated with in-
creasing concentrations of fA   for 24 h. In contrast,
CD36 /   macrophages produced a dose-dependent in-
crease in MCP-1 protein secretion accumulating  800 pg/
ml in the medium after 24 h of stimulation with fA  at 10
 g/spot (Fig. 2 B). CD36 /  and CD36 /  macrophages
produced equal amounts of MCP-1 when stimulated with
bacterial LPS (unpublished data).
To determine whether CD36 is necessary for MCP-1
mRNA accumulation in response to fA , RNA was iso-
lated from CD36 /   and CD36 /   peritoneal macro-
phages stimulated for 24 h with increasing concentrations
of fA . MCP-1 mRNA levels were determined using
Q-PCR. MCP-1 mRNA was not induced in CD36 / 
macrophages after 24 h of stimulation with a dose range of
fA . In contrast, fA  induced a dose-dependent increase
in MCP-1 mRNA accumulation in CD36 /   macro-
phages, reaching 100-fold induction over unstimulated
CD36 /  macrophages after 24 h of fA  stimulation (10
 g/spot; Fig. 2 C). CD36 /  and CD36 /  macrophages
showed comparable increases in their MCP-1 mRNA lev-
els when stimulated with increasing concentrations of bac-
terial LPS (Fig. 2 D). These data demonstrate that fA  in-
duces MCP-1 protein secretion and mRNA accumulation
in peritoneal macrophages in a CD36-dependent manner,
Figure 2. fA -stimulated chemoattractant
production in microglia and macrophages is
CD36 dependent. (A) Primary mouse mi-
croglia from CD36 /  mice were cultured
on multispot slides and stimulated with the
indicated concentrations of fA  and revA 
for 24 h, and the supernatant was collected
and assayed for THP-1 chemotactic activity.
CD36 /  microglia produce significantly less
chemotactic activity for THP-1 cells when
stimulated with fA  compared with CD36 / 
microglia (n   7). (B) Thioglycollate-elic-
ited peritoneal macrophages from CD36 / 
and CD36 /  mice cultured on multispot
slides were incubated with the indicated
concentrations of fA  for 24 h. MCP-1 re-
leased into their supernatant was measured
by ELISA. (C) MCP-1 mRNA levels in
CD36 /  and CD36 /  macrophages stimu-
lated as described above with the indicated
concentrations of fA  (n   3). (D) MCP-1
mRNA levels in CD36 /  and CD36 / 
macrophages stimulated with 1, 10, or 100
ng/ml LPS (n   3). Each data point is the
average   SEM of triplicate measurements
from the indicated number of experiments
(n). *, P   0.003.T
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1661 El Khoury et al.
and that at a wide range of LPS concentrations, including
doses of LPS producing the same fold stimulation as fA ,
CD36 was not necessary for LPS-induced up-regulation of
MCP-1 mRNA.
CD36 Is Required for fA  Induction of TNF , IL-1 , and
Several Chemokine mRNAs. Proinflammatory cytokines
such as TNF  and IL-1  are up-regulated in the brains of
AD patients and transgenic mice with AD-like pathology
(21–23) and secreted by fA -stimulated microglia and
macrophages in culture (24, 25). To determine whether
CD36 is required for up-regulation of TNF  and IL-1 
mRNA levels after fA  stimulation, we used Q-PCR and
CD36 /  and CD36 /  macrophages. CD36 /  macro-
phages markedly up-regulated mRNA for TNF  and IL-1 
in response fA  (12- and 24-fold, respectively; Fig. 3 A). In
marked contrast, CD36 /  macrophages had a minimal re-
sponse to fA  stimulation and had significantly less TNF 
and IL-1  mRNA (Fig. 3 A). Interestingly, as observed
with microglia (Fig. 1 E), fA  also induced the accumula-
tion of mRNA for additional chemokines such as MIP-1 ,
MIP-1 , MIP-2, and KC/CXCL1 in macrophages (Fig.
3 A). These chemokines were also induced in a CD36-
dependent manner. Not all chemokines were induced by
fA  stimulation of macrophages as can be seen by the lack
of monocyte-derived chemokine (MDC)/CCL22 induc-
tion (Fig. 3 A). The accumulation of mRNA encoding
these cytokines and chemokines was equivalent in CD36 / 
and CD36 /  macrophages stimulated with increasing con-
centrations of bacterial LPS, indicating that the absence of
CD36 did not result in a general loss in cytokine or che-
mokine responsiveness (Fig. 3 B). These data demonstrate
that CD36 plays an important role in the induction of
proinflammatory cytokines and chemokines in response to
fA  stimulation. These data also show that at a wide range
of LPS concentrations, including doses of LPS producing
similar fold stimulation as fA , CD36 was not necessary for
LPS-induced up-regulation of these proinflammatory cyto-
kines and chemokines, confirming that the machinery to
produce these proinflammatory molecules is intact in
CD36 /  mice. In addition, these data show that fA  stim-
ulation induces similar chemokine responses in microglia
and macrophages.
CD36 Is Required for fA -induced ROS Production by Mac-
rophages. Binding of microglia to fA  leads to ROS pro-
duction (9, 13). Previously, we found that antibodies to
CD36 inhibited  50% of the ROS produced by microglia
stimulated with fA  (13). Therefore, we used CD36 / 
macrophages to extend these findings and found that
CD36 /  macrophages produced essentially no ROS when
stimulated with fA  compared with the robust production
of ROS by similarly treated CD36 /  macrophages (Fig. 4,
A and B). CD36 /  and CD36 /  macrophages produced
essentially no ROS when stimulated with revA  (Fig. 4 C)
and produced equal amounts of ROS when stimulated
with zymosan (Fig. 4, D–F). These data demonstrate that
CD36 is required for fA  induction of ROS production by
macrophages and suggest that antibodies to CD36 are not
completely effective at inhibiting CD36 function.
CD36 Is Not Necessary for Adhesion of Microglia and Macro-
phages to fA . We have recently shown that cells trans-
fected with CD36 gain the ability to adhere to multispot
glass slides coated with CIV and fA , and that two anti-
CD36 inhibitory antibodies, SM  and NL07, blocked this
adhesion (13). To determine if CD36 is necessary for adhe-
sion of microglia and macrophages to fA -coated surfaces,
we performed the same adhesion assay in the presence of
antibodies to CD36 using microglia and macrophages iso-
lated from wild-type mice. As expected and previously re-
ported (13), microglia adhere avidly to multispot slides
coated with CIV and fA  but not to surfaces coated with
CIV alone (unpublished data). Anti-CD36 antibodies had
no effect on adhesion of wild-type microglia to surfaces
coated with CIV and fA  (Fig. 5 A), even though these
same antibodies inhibited adhesion of CD36 transfected
cells to surfaces coated with CIV and fA  (13). We also re-
peated this adhesion experiment using CD36 /  microglia.
CD36 /  and CD36 /  microglia bound comparably well
to fA -coated surfaces (11,995   900 vs. 14,450   1,575
cells/spot, respectively; Fig. 5 B). These data indicate that
Figure 3. fA   up-regulates chemokine and cytokine mRNA in
CD36 /  but not in CD36 /  macrophages. Peritoneal macrophages
from CD36 /  and CD36 /  mice cultured on multispot slides were in-
cubated with 10  g/spot of fA  or revA  (A), or 1, 10, or 100 ng/ml
LPS (B) for 24 h. mRNA was harvested for Q-PCR measurement of the
indicated chemokines and cytokines. Each data point is the average  
SEM of two independent experiments each performed in duplicate.T
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1662 CD36 and Alzheimer’s Disease
although CD36 is capable of binding fA , this interaction
is not required for microglial adhesion to a fA -coated sub-
strate. Although other receptors mediate this adhesion re-
sponse, our data demonstrate that they are unable to com-
pensate for the loss of CD36 in the fA -stimulated
signaling activation pathway.
CD36 Is Expressed on Adult Mouse Microglia in Culture and
Mediates fA -induced ROS Production. Microglia in AD
brains and human fetal microglia express CD36 (13). We
confirmed that adult mouse microglia also express CD36.
Neonatal microglia, adult macrophages, and adult microglia
stain with mAb specific for CD36 but not with a control
isotype matched mAb (Fig. 6, A–F). Using Q-PCR we
also found that CD36 and SR-A are expressed at the
mRNA level. Interestingly, mRNA levels for other scav-
enger receptors, including SRB-1, SR-F, and Lox-1, were
negligible in unstimulated adult mouse microglia (Fig.
6 G). To determine whether CD36 expressed on adult
mouse microglia plays a similar role to CD36 expressed on
neonatal microglia and adult macrophages in mediating the
response to fA , we measured ROS production in adult
mouse microglia isolated from CD36 /  and CD36 / 
mice stimulated with fA  or revA . As expected, adult
CD36 /  microglia produced essentially no ROS when
stimulated with fA  compared with the robust production
of ROS by similarly treated adult CD36 /  microglia (Fig.
6 H). These data confirm that CD36 plays a key role in
fA -induced ROS production in adult mouse microglia
and show that adult mouse microglia behave similarly to
neonatal mouse microglia and adult macrophages in terms
of their responses to fA .
Intraperitoneal Injection of fA  Leads to a CD36-dependent
Inflammatory Response. Intraperitoneal injection of proin-
flammatory stimuli is an established model for studying
recruitment of leukocytes in vivo (16). To begin to ex-
plore the role of CD36 in fA -stimulated inflammatory
responses in vivo, we injected 100  g fA  into the peri-
toneum of CD36 /  and CD36 /  mice. 24 h later, the
cellular content of the peritoneal cavity was recovered by
peritoneal lavage and analyzed. Intraperitoneal injection
of fA  led to a fourfold increase in the number of mono-
cytes recruited into the peritoneum of CD36 /  mice
compared with injection of carrier alone (Fig. 7 A).
Monocytes/macrophages constituted  60% of the in-
flammatory cells recruited to the peritoneum with the re-
maining cells being  20% neutrophils and 20% eosino-
phils as determined by microscopic analysis of stained
cytospin slides (Fig. 7 C). Intraperitoneal injection of fA 
into CD36 /  mice failed to induce the recruitment of
leukocytes into the peritoneum (Fig. 7 A). As a control
for the ability of CD36 /  macrophages to migrate into
the peritoneum in response to a non-CD36–dependent
Figure 4. fA -stimulated but not zymo-
san-stimulated ROS production is CD36
dependent. Macrophages from CD36 / 
and CD36 /  mice were cultured on multi-
spot slides and incubated with 10  g/spot
fA , revA , 1 mg/ml zymosan, or carrier
alone for 1 h. ROS production was assayed
by the NBT reduction method, which pro-
duces visible dark blue formazan deposits. A
representative field is shown (original mag-
nification,  10). The amount of deposited
formazan (dark areas) was quantified using
digital video microscopy and Scion image
analysis software as arbitrary units per 105
cells. (A–C) fA -stimulated macrophages.
(D–F) Zymosan-stimulated macrophages.
Each data point is the average   SEM of 10
measurements per sample from 3 indepen-
dent experiments.
Figure 5. Microglia and macrophage adhesion to
fA -coated surfaces is CD36 independent. (A) 25  
103 primary mouse microglia macrophages were al-
lowed to adhere to multispot slides coated with CIV
and 1  g/spot fA  for 1 h in the presence of the indi-
cated anti-CD36 mAb (10  g/ml). Nonadherent cells
were washed away and the number of adherent cells
was counted. (B) The same experiment was repeated
using microglia from CD36 /  and CD36 /  mice.
Each data point is the average   SEM of triplicate
measurements from three independent experiments.T
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inflammatory stimulus, we found that intraperitoneal zy-
mosan induced equivalent numbers of mononuclear cell
recruitment into the peritoneum of CD36 /   and
CD36 /  mice (Fig. 7 B). We confirmed this in vivo con-
trol in vitro by demonstrating that macrophages from
CD36 /   and CD36 /   mice chemotaxed equally to
MCP-1 (unpublished data).
Microglial Recruitment to Intracerebral Sites of fA  Deposition
Is CD36 Dependent. Stereotaxic intracerebral injection of
fA  in aged primates induces a strong microglial reaction
and neurotoxicity (5), and has been used as a model for
studying the effects of fA  in vivo and for microglial func-
tion in AD (5, 6). To determine the role of CD36 in the
recruitment of microglia to sites of intracerebral fA  depo-
sition, we stereotaxically microinjected 2  g fA  in the
cortex of 5–6-mo-old CD36 /  and CD36 /  mice. As a
control, we injected 2  g nonfibrillar revA  in the cortex
of the opposite hemisphere. 48 h later, the mice were killed
and serial brain sections were analyzed for the number of
microglia recruited to the site of microinjection using im-
munofluorescent staining with F4/80, a mAb that binds a
well-established microglial and macrophage cell surface
marker (7). Nuclei were visualized by costaining with the
nucleic acid stain DAPI. Stereotaxic microinjection of fA 
led to significant microglial cell recruitment in CD36 / 
mice quantified by measuring fluorescence intensity of F4/
80  cells per site of injection per brain section (40   3.9
fluorescence units; Fig. 8, A and E). As a control, microin-
jection of an equal amount of revA  induced significantly
less microglial cell recruitment in CD36 /  mice (14.5   2
fluorescence units; Fig. 8, B and E). In contrast to CD36 / 
mice, injection of fA  into CD36 /  mice induced signifi-
cantly less microglial cell recruitment, and no significant
difference was observed between fA  and revA  in the
CD36 /  mice (15    1.7 vs. 7.8    3.5, respectively).
These data demonstrate for the first time that CD36 is re-
quired for the recruitment of microglia to sites of fA  de-
position in vivo.
Figure 6. CD36 is expressed on adult
mouse microglia and mediates fA -
induced ROS production. (A–F) Neonatal
mouse microglia (A and D), adult mouse
microglia (B and E), or peritoneal mouse
macrophages (C and F) were stained with
mAb to mouse CD36 or isotype-matched
control followed by FITC-labeled second-
ary antibody, visualized by fluorescence mi-
croscopy, and digitally photographed. (G)
mRNA from adult mouse microglia was
harvested for Q-PCR using probes specific
for SR-A, SR-B1, SR-F, CD36, and Lox-1.
(H) Adult microglia from CD36 /   and
CD36 /  mice were cultured on multispot
slides and incubated with 10  g/spot fA  or
revA  for 1 h. ROS production was assayed
by the NBT reduction method, which pro-
duces visible dark blue formazan deposits.
The amount of deposited formazan was
quantified using digital video microscopy
and Scion image analysis software.
Figure 7. fA -induced recruitment of monocytes into the peritoneum is CD36 dependent. (A) CD36 /  or CD36 /  mice were injected intraperito-
neally with 100  g fA . 24 h later, the peritoneal cells were harvested by lavage and the number of total cells counted was and differential cell counts
were performed on 500 Heme3-stained cells per mouse (C). fA  lead to recruitment of monocytes in CD36 /  (n   10) but not CD36 /  (n   8) mice.
Injection of carrier alone (PBS with 1 mg/ml BSA) did not induce significant monocyte recruitment. (B) CD36 /  and CD36 /  mice injected with
1 mg zymosan recruited equivalent amounts of monocytes after 24 h. Each data point is the average   SEM of results from the indicated number of mice
(n) per genotype. *, P   0.005.T
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Discussion
Recruitment of activated leukocytes to sites of tissue in-
jury is an important initial step in the inflammatory process
(26). In the case of AD, the initial injurious inflammatory
stimulus is thought to be the deposition of insoluble extra-
cellular aggregates of fA . These fA  deposits lead to an in-
nate host response characterized by the accumulation of ac-
tivated microglia (2, 27). The molecular events that occur
between the deposition of fA  and recruitment and activa-
tion of microglia have not been identified. The data pre-
sented here show that the class B2 scavenger receptor CD36
is necessary for fA -induced activation of microglia and
macrophages. Binding of fA  to CD36 mediates activation
of microglia to produce ROS, the proinflammatory cyto-
kines IL-1  and TNF , and a number of chemokines active
on microglial cells. ROS and cytokines are thought to ini-
tiate and/or propagate the neurotoxic effects of fA  (1, 3, 6,
28), and we have proposed that CD36-dependent chemo-
kine secretion promotes the recruitment of additional acti-
vated microglia, which would amplify the local neurotoxic
inflammatory response. In fact, using two different in vivo
assays we demonstrated that fA  induces the recruitment of
microglia and macrophages in vivo in a CD36-dependent
fashion. CD36 is therefore a key molecular link between
recognition of extracellular fA  and microglial activation.
Our use of stereotaxic intracerebral microinjection of
fA  into genetically deficient mice represents a novel ex-
tension of this technique previously used in wild-type pri-
mates and rats (5, 6). Using this approach, we were able to
demonstrate a critical role for a single gene, CD36, in initi-
ating the inflammatory response to fA  in the brain in
vivo. Thus, stereotaxic intracerebral microinjection of fA 
in genetically deficient mice might be used as a rapid in
vivo method for dissecting the molecular and cellular com-
ponents of the brain’s response to fA . This assay also can
be used for the rapid screening of novel therapeutics for
their ability to interfere with this pathologic process.
Although the data in this work clearly indicate that
CD36 is necessary for fA -induced signal transduction in
macrophages and microglia, other receptors on these cells
participate in the interaction with fA , as we found that
CD36 /  macrophages and microglia adhered normally to
fA -coated surfaces. Indeed, another scavenger receptor,
SR-A, has been shown to play a nonredundant role in ad-
hesion of macrophages to fA  (9) and data using a poly-
clonal antibody to the receptor for advanced glycation end
products also suggested that it may play a role in fA -
induced microglial activation (30). It is likely that SR-A
and CD36 and perhaps receptor for advanced glycation end
products play complementary roles in the macrophage re-
sponse to fA . Interestingly, it has been proposed that SR-A
and CD36 are similarly involved in the macrophage re-
sponse to oxidized low density lipoprotein (29). Thus,
CD36 is a necessary signaling component of a pattern rec-
ognition receptor complex on macrophages and microglia
that recognize modified host proteins. This interaction
leads to cellular activation and initiation of a local inflam-
matory reaction that is a defining feature of chronic inflam-
matory diseases, such as AD and atherosclerosis.
Figure 8. Intracerebral fA -
induced recruitment of microglia
is CD36 dependent. CD36 / 
(A and B) or CD36 /  (C and
D) mice stereotaxically microin-
jected with 2  g fA  (A and C)
or revA  (B and D) into oppo-
site hemispheres. 48 h later, mice
were killed and 20- m frozen
sections were stained with F4/80
(green) and DAPI (blue; original
magnification,  4). The fluores-
cence intensity of F4/80 staining
representing the number of mi-
croglia per injection site was
quantified by digital imaging
analysis (E). A higher magnifica-
tion image showing details of cy-
toplasmic F4/80 and nuclear
DAPI staining is shown in F.
Each data point is the average  
SEM of five different sections per
mouse and is a representative of
five to seven mice per genotype
with similar results. *, P   0.005.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1665 El Khoury et al.
Recent attention has been focused on the Toll-like re-
ceptor family of “pattern recognition receptors” as critical
activators of the innate immune system. Toll-like receptors
are activated by pathogen-associated molecular structures
(31) as well as endogenous molecular structures such as heat
shock proteins (32) and IgM-chromatin immune complexes
(33). Our study now extends this concept to a less well un-
derstood family of pattern recognition receptors, the scav-
enger receptors. Although the scavenger receptors may
have evolved to clear the body of nonnative proteins, we
show here that when host proteins are modified to form
fibrils they can bind scavenger receptors and trigger a local
chronic inflammatory response. Our study has clearly dem-
onstrated that CD36 is a critical component of this innate
receptor complex that mediates a wide range of proinflam-
matory events induced by fA . CD36 as such represents a
defined molecular target for therapeutic intervention in AD
and, perhaps, other chronic inflammatory diseases.
We thank Dr. E. Antonio Chiocca from the Neurosurgical Service
at Massachusetts General Hospital for use of the stereotaxic instru-
ments and Marie McKee from the Renal Unit at Massachusetts Gen-
eral Hospital for assistance with the processing of frozen sections.
This work was supported by National Institutes of Health grants
NS41330 (to J. El Khoury), R01AG20255-01 (to K.J. Moore), P01
DK50305 (to M.W. Freeman and A.D. Luster), R01 HL45098 (to
M.W. Freeman), and grants from the Alzheimer’s Disease Research
Program of the American Health Assistance Foundation and the
Harvard Center for Neurodegeneration and Repair (to J. El
Khoury).
Submitted: 3 September 2002
Revised: 9 April 2003
Accepted: 9 April 2003
References
1. Itagaki, S., P.L. McGeer, H. Akiyama, S. Zhu, and D.
Selkoe. 1989. Relationship of microglia and astrocytes to
amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24:
173–182.
2. McGeer, P.L., S. Itagaki, H. Tago, and E.G. McGeer. 1987.
Reactive microglia in patients with senile dementia of the
Alzheimer type are positive for the histocompatibility glyco-
protein HLA-DR. Neurosci. Lett. 79:195–200.
3. Giulian, D., L.J. Haverkamp, J.H. Yu, W. Karshin, D. Tom,
J. Li, J. Kirkpatrick, L.M. Kuo, and A.E. Roher. 1996. Spe-
cific domains of beta-amyloid from Alzheimer plaque elicit
neuron killing in human microglia. J. Neurosci. 16:6021-6037.
4. Frautschy, S.A., F. Yang, M. Irrizarry, B. Hyman, T.C.
Saido, K. Hsiao, and G.M. Cole. 1998. Microglial response
to amyloid plaques in APPsw transgenic mice. Am. J. Pathol.
152:307–317.
5. Geula, C., C.K. Wu, D. Saroff, A. Lorenzo, M. Yuan, and
B.A. Yankner. 1998. Aging renders the brain vulnerable to
amyloid beta-protein neurotoxicity. Nat. Med. 4:827–831.
6. Weldon, D.T., S.D. Rogers, J.R. Ghilardi, M.P. Finke, J.P.
Cleary, E. O’Hare, W.P. Esler, J.E. Maggio, and P.W. Man-
tyh. 1998. Fibrillar beta-amyloid induces microglial phagocy-
tosis, expression of inducible nitric oxide synthase, and loss of
a select population of neurons in the rat CNS in vivo. J. Neu-
rosci. 18:2161–2173.
7. Bornemann, K.D., K.H. Wiederhold, C. Pauli, F. Ermini,
M. Stalder, L. Schnell, B. Sommer, M. Jucker, and M.
Staufenbiel. 2001. Abeta-induced inflammatory processes in
microglia cells of APP23 transgenic mice. Am. J. Pathol. 158:
63–73.
8. Selkoe, D.J. 1991. The molecular pathology of Alzheimer’s
disease. Neuron. 6:487–498.
9. El Khoury, J., S.E. Hickman, C.A. Thomas, L. Cao, S.C. Sil-
verstein, and J.D. Loike. 1996. Scavenger receptor-mediated
adhesion of microglia to beta-amyloid fibrils. Nature. 382:
716–719.
10. Paresce, D.M., R.N. Ghosh, and F.R. Maxfield. 1996. Mi-
croglial cells internalize aggregates of the Alzheimer’s disease
amyloid beta-protein via a scavenger receptor. Neuron. 17:
553–565.
11. Christie, R.H., M. Freeman, and B.T. Hyman. 1996. Ex-
pression of the macrophage scavenger receptor, a multifunc-
tional lipoprotein receptor, in microglia associated with senile
plaques in Alzheimer’s disease. Am. J. Pathol. 148:399–403.
12. Honda, M., H. Akiyama, Y. Yamada, H. Kondo, Y.
Kawabe, M. Takeya, K. Takahashi, H. Suzuki, T. Doi, A.
Sakamoto, et al. 1998. Immunohistochemical evidence for a
macrophage scavenger receptor in Mato cells and reactive
microglia of ischemia and Alzheimer’s disease. Biochem. Bio-
phys. Res. Commun. 245:734–740.
13. Coraci, I.S., J. Husemann, J.W. Berman, C. Hulette, J.H.
Dufour, G.K. Campanella, A.D. Luster, S.C. Silverstein, and
J.B. El-Khoury. 2002. CD36, a class B scavenger receptor, is
expressed on microglia in Alzheimer’s disease brains and can
mediate production of reactive oxygen species in response to
beta-amyloid fibrils. Am. J. Pathol. 160:101–112.
14. Antic, A., K.A. Dzenko, and J.S. Pachter. 2000. Engagement
of the scavenger receptor is not responsible for beta-amyloid
stimulation of monocytes to a neurocytopathic state. Exp.
Neurol. 161:96–101.
15. Moore, K.J., J. El Khoury, L.A. Medeiros, K. Terada, C.
Geula, A.D. Luster, and M.W. Freeman. 2002. A CD36-ini-
tiated signaling cascade mediates inflammatory effects of beta-
amyloid. J. Biol. Chem. 277:47373–47379.
16. Thomas, C.A., Y. Li, T. Kodama, H. Suzuki, S.C. Silver-
stein, and J. El Khoury. 2000. Protection from lethal gram-
positive infection by macrophage scavenger receptor–depen-
dent phagocytosis. J. Exp. Med. 191:147–156.
17. Basu, A., J.K. Krady, M. O’Malley, S.D. Styren, S.T. De-
Kosky, and S.W. Levison. 2002. The type 1 interleukin-1 re-
ceptor is essential for the efficient activation of microglia and
the induction of multiple proinflammatory mediators in re-
sponse to brain injury. J. Neurosci. 22:6071–6082.
18. El Khoury, J., C.A. Thomas, J.D. Loike, S.E. Hickman, L.
Cao, and S.C. Silverstein. 1994. Macrophages adhere to glu-
cose-modified basement membrane collagen IV via their
scavenger receptors. J. Biol. Chem. 269:10197–10200.
19. Ishizuka, K., T. Kimura, R. Igata-yi, S. Katsuragi, J. Taka-
matsu, and T. Miyakawa. 1997. Identification of monocyte
chemoattractant protein-1 in senile plaques and reactive mi-
croglia of Alzheimer’s disease. Psychiatry Clin. Neurosci. 51:
135–138.
20. Meda, L., P. Baron, E. Prat, E. Scarpini, G. Scarlato, M.A.
Cassatella, and F. Rossi. 1999. Proinflammatory profile of cy-
tokine production by human monocytes and murine micro-
glia stimulated with beta-amyloid. J. Neuroimmunol. 93:45–
52.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1666 CD36 and Alzheimer’s Disease
21. Sheng, J.G., W.S. Griffin, M.C. Royston, and R.E. Mrak.
1998. Distribution of interleukin-1-immunoreactive micro-
glia in cerebral cortical layers: implications for neuritic plaque
formation in Alzheimer’s disease. Neuropathol. Appl. Neuro-
biol. 24:278–283.
22. Grammas, P., and R. Ovase. 2001. Inflammatory factors are
elevated in brain microvessels in Alzheimer’s disease. Neuro-
biol. Aging. 22:837–842.
23. Sly, L.M., R.F. Krzesicki, J.R. Brashler, A.E. Buhl, D.D.
McKinley, D.B. Carter, and J.E. Chin. 2001. Endogenous
brain cytokine mRNA and inflammatory responses to li-
popolysaccharide are elevated in the Tg2576 transgenic
mouse model of Alzheimer’s disease. Brain Res. Bull. 56:581–
588.
24. Meda, L., M.A. Cassatella, G.I. Szendrei, L. Otvos, Jr., P.
Baron, M. Villalba, D. Ferrari, and F. Rossi. 1995. Activation
of microglial cells by beta-amyloid protein and interferon-
gamma. Nature. 374:647–650.
25. Combs, C.K., J.C. Karlo, S.C. Kao, and G.E. Landreth.
2001. beta-Amyloid stimulation of microglia and monocytes
results in TNFalpha-dependent expression of inducible nitric
oxide synthase and neuronal apoptosis. J. Neurosci. 21:1179–
1188.
26. Luster, A.D. 1998. Chemokines–chemotactic cytokines that
mediate inflammation. N. Engl. J. Med. 338:436–445.
27. Dickson, D.W., J. Farlo, P. Davies, H. Crystal, P. Fuld, and
S.H. Yen. 1988. Alzheimer’s disease. A double-labeling im-
munohistochemical study of senile plaques. Am. J. Pathol.
132:86–101.
28. El Khoury, J., S.E. Hickman, C.A. Thomas, J.D. Loike, and
S.C. Silverstein. 1998. Microglia, scavenger receptors, and
the pathogenesis of Alzheimer’s disease. Neurobiol. Aging. 19:
S81–S84.
29. Maxeiner, H., J. Husemann, C.A. Thomas, J.D. Loike, J. El
Khoury, and S.C. Silverstein. 1998. Complementary roles for
scavenger receptor A and CD36 of human monocyte-
derived macrophages in adhesion to surfaces coated with ox-
idized low-density lipoproteins and in secretion of H2O2. J.
Exp. Med. 188:2257–2265.
30. Lue, L.F., D.G. Walker, L. Brachova, T.G. Beach, J. Rogers,
A.M. Schmidt, D.M. Stern, and S.D. Yan. 2001. Involve-
ment of microglial receptor for advanced glycation endprod-
ucts (RAGE) in Alzheimer’s disease: identification of a cellu-
lar activation mechanism. Exp. Neurol. 171:29–45.
31. Medzhitov, R., and C. Janeway, Jr. 2000. The Toll receptor
family and microbial recognition. Trends Microbiol. 8:452–
456.
32. Ohashi, K., V. Burkart, S. Flohe, and H. Kolb. 2000. Cutting
edge: heat shock protein 60 is a putative endogenous ligand
of the toll-like receptor-4 complex. J. Immunol. 164:558–
561.
33. Leadbetter, E.A., I.R. Rifkin, A.M. Hohlbaum, B.C. Beau-
dette, M.J. Shlomchik, and A. Marshak-Rothstein. 2002.
Chromatin-IgG complexes activate B cells by dual engage-
ment of IgM and Toll-like receptors. Nature. 416:603–607.